Effect of Evolocumab on Coronary Artery Plaque Volume and Composition by CCTA and Microcalcification by F18-NaF PET
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This study will quantify changes in coronary plaque volumes and plaque composition in
patients treated with evolocumab.
Previous intravascular ultrasound studies have shown that treatment with a lipid-lowering
PCSK9 enzyme inhibitor, such as evolocumab, to be associated with a reduction of the fatty
deposits that cause plaque in the arteries, however, it is not known how evolocumab affects
specific coronary plaque types and plaque inflammation.
Investigators will use quantitative assessment of non-invasive coronary computed tomography
angiography (CCTA) and positron emission tomography (PET)imaging to evaluate functional
changes in plaque burden, plaque composition and vascular inflammation before and after
treatment with evolocumab.
Investigators propose to show that patients treated with evolocumab in combination with
statins demonstrate a greater reduction of coronary non-calcified plaque volume, thereby
reducing the number of future cardiac events.